Search Results
May 26, 2026, 08:47 ET NEW POLL HIGHLIGHTS THE CRITICAL ROLE COMMUNICATION PLAYS IN CAREGIVING
ADULTSProfessional Help Can Make A Significant Positive DifferenceROCKVILLE, Md., May 26, 2026 /PRNewswire/ -- Communication between caregivers and those in their care is critical. When communication
More news about: American Speech-Language-Hearing Association (ASHA)
May 26, 2026, 08:38 ET Brave Healer Productions Releases "From Burnout to Burning Bright: The Ultimate Guide to Prevention, Healing and Recovery"
BETHESDA, Md., May 26, 2026 /PRNewswire/ -- There comes a point when holding everything together no longer works — when exhaustion, fear, and heartbreak converge, leaving people wondering whether anything of themselves remains.
More news about: Brave Healer Productions
May 26, 2026, 08:33 ET Neema Hospitality Launches Annual Summer Charity Promotion in Support of Team Fox for Parkinson's Research
all properties for guests who want to give directly. The promotion runs across all 10 properties under Choice Hotels, Marriott, and IHG brands in PA, MD, and WV.Hotels for a Cure started as a personal CHOICE to use our business as a force for good. This year, it carries more weight than ever.
More news about: Neema Hospitality
May 26, 2026, 08:33 ET Consano Bio Initiates Phase 1 Clinical Trial of C-1101, a Potential First-in-Class, Non-Opioid Therapy for Chronic Sciatica
"People living with chronic lumbosacral radiculopathy have limited treatment options and often struggle to find lasting relief," said Paul Verrills, MD, lead investigator in Australia for the C-1101-101 study and founder of MetroPain in Melbourne, Australia. "We are eager to evaluate C-1101 in a
More news about: Consano Bio
May 26, 2026, 08:30 ET Executing MRD in Oncology Trials: From Protocol Design to Commercial Impact, Upcoming Webinar Hosted by Xtalks
Health, Wael Harb (Moderator), MD, MBA, Head of R&D and Scientific Strategy, Early Phase Oncology; Patrick Melvin, Vice President, Therapeutic Strategy & Innovation; Jacquelyn Ritchie, MPH, Therapeutic Area Head of Hematology/Oncology; and Muaiad Kittaneh, MD, MBA, FACP, Global Head of R&D
More news about: Xtalks
May 26, 2026, 08:30 ET Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
visceral crisis and started chemotherapy based on an initial diagnosis of triple-negative breast cancer. Her treating oncologist, Vitor H. Pastorini Filho, MD, a board-certified hematologist and medical oncologist, questioned whether the clinical picture fit and ordered comprehensive molecular profiling with
More news about: Caris Life Sciences
May 26, 2026, 08:10 ET Menarini Group、American Society of Clinical Oncology (ASCO)の2026年年次総会で新データを発表
てのエラセストランを検証するELEGANT試験の最新結果が、 本学会で 発表される予定です。 また、芽球性形質細胞様樹状細胞腫瘍（BPDCN）患者を対象としたタグラキソフスプの新たな第II相併用療法に関するデータも発表が採択されており、The University of Texas MD Anderson Cancer Centerのがん内科白血病部門のNaveen Pemmaraju医学博士（教授）が発表を行う予定です。さらに、 StemlineのパートナーであるKaryopharm Therapeuticsが、JAKi未治療の骨髄線維症（MF）患者を対象としたセリンエキソールの第3相SENTRY試験から、最新の口頭発表を行います。Selinexorは米国ではKaryopharm
More news about: Menarini Industrie Farmaceutiche Riunite
May 26, 2026, 08:05 ET Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
GERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen,
More news about: Precigen, Inc.
May 26, 2026, 08:00 ET b.well Connected Health and myTomorrows Announce Partnership to Transform Clinical Trial Access for Patients
connect eligible patients to relevant clinical trial opportunities earlier in their care journeyBALTIMORE, Md. and AMSTERDAM, May 26, 2026 /PRNewswire/ -- b.well
More news about: b.well Connected Health and myTomorrows
May 26, 2026, 08:00 ET Prescription cannabis telehealth platform launches in Colorado, with multi-state expansion planned
prescription cannabis care with a board-certified clinician after confirming their eligibility through the Cope Now telehealth platform."Sean Arora, MD, co-founder and CEO of Arora Health and one of the prescribing physicians on the Cope Now platform said "We believe physician-led cannabinoid care programs
More news about: Kazmira Therapeutics
May 26, 2026, 08:00 ET Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
Phase 3 RUBY and TOPAZ trials, and reinforces our commitment to advancing comprehensive treatment options for patients with gout."Nihar Bhakta, MD, Chief Medical Officer of Crystalys Therapeutics, added, "Many patients cannot take or tolerate existing therapies to achieve target uric acid levels
More news about: Crystalys Therapeutics
May 26, 2026, 08:00 ET LUCA MINING CORP. REPORTS STRONG FIRST QUARTER 2026 RESULTS
condensed consolidated interim financial statements for the three months ended March 31, 2026 and associated Management's Discussion and Analysis ("MD&A") which are available on the Company's website,
More news about: Luca Mining Corp.
May 26, 2026, 07:30 ET Cogent Communications Announces Definitive Agreement to Sell 10 Data Center Facilities
sponsored by I Squared Capital. The 10 facilities are located in Phoenix, AZ, Anaheim, CA, Burbank, CA, Stockton, CA, Atlanta, GA, Chicago, IL, Elkridge, MD, Kansas City, MO, Nashville, TN and Houston, TX.
More news about: Cogent Communications Holdings, Inc.
May 26, 2026, 07:30 ET Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
ME/CFS and related post-acute infection syndromes often face lengthy diagnostic journeys and limited objective testing options," said Dr. Sean Knight, MD, PhD, Principal Investigator at the Lydia Becker Institute of Immunology and Inflammation, University of Manchester, and Consultant Respiratory Physician
More news about: Virax BioLabs Group Limited
May 26, 2026, 06:45 ET Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases
prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection BETHESDA, Md., May 26, 2026 /PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology
More news about: Vaccine Company
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
metastatic colorectal cancer (mCRC): A phase II studyAbstract: 3576Date: May 30, 2026First Author: David Berz, MD, PhD, Department of Oncology, Valkyrie Clinical Trials, IncAbout AkesoAkeso (HKEX: 9926.HK) is a leading biopharmaceutical
More news about: Akeso, Inc.
May 25, 2026, 22:53 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
trial, including the primary endpoint eGFR, key secondary endpoints as well as safety results. The presentation will be delivered by Dr Robert Montgomery, MD PhD, New York University Langone Transplant Institute and investigator in the ConfIdeS trial.Title: Superior 1-year eGFR Among Highly Sensitized
More news about: Hansa Biopharma AB
May 25, 2026, 22:52 ET Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
trial, including the primary endpoint eGFR, key secondary endpoints as well as safety results. The presentation will be delivered by Dr Robert Montgomery, MD PhD, New York University Langone Transplant Institute and investigator in the ConfIdeS trial.Title: Superior 1-year eGFR Among Highly Sensitized
More news about: Hansa Biopharma AB
May 25, 2026, 17:50 ET Sabio Announces First Quarter 2026 Results
planning.Refer to reconciliation to Adjusted EBITDA and Gross Revenue under the "Selected Financials" section of this release and in the Company's MD&A for the three months ended March 31, 2026 and March 31, 2025, copies of which can be found under Sabio Holdings Inc.'s profile on SEDAR Plus at sedarplus.ca.Reoccurring
More news about: Sabio Inc.
May 25, 2026, 11:56 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 새로운 데이터 발표
병용요법을 평가하는 2상 CAPELA가 포함된다. 마지막으로, 재발 위험이 높은 림프절 양성 조기 유방암에서 보조치료제로서 엘라세스트란트를 탐색하는 ELEGANT 시험의 최신 내용도 학회에서 발표될 예정이다.또한 텍사스대학교 MD 앤더슨 암센터(University of Texas MD Anderson Cancer Center) 암의학부 백혈병학과 교수인 나빈 펨마라주(Naveen Pemmaraju) 박사가 발표할 모구성 형질세포양 수지상세포 종양(BPDCN) 환자 대상 타그락소푸스프 병용요법의 신규 2상 데이터도 발표 대상으로
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 09:47 ET Menarini anuncia nuevos datos en la reunión anual de la Sociedad Americana de Oncología Clínica (ASCO) 2026
(BPDCN), que serán presentados por el Dr. Naveen Pemmaraju, profesor del Departamento de Leucemia, División de Medicina Oncológica, Centro Oncológico MD Anderson de la Universidad de Texas. Además, el socio de Stemline, Karyopharm Therapeutics, presentará una presentación oral de última hora del ensayo
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:30 ET Expert.ai and Fincons Group Join Forces to Bring Neuro-Symbolic AI to Data-Driven Businesses
architectures and systems integration to bring neuro-symbolic AI into core business processes. ROCKVILLE, Md., May 25, 2026 /PRNewswire/ -- Expert.ai, a leading provider of enterprise AI solutions for business value creation,
More news about: expert.ai
May 25, 2026, 08:13 ET Menarini Group gibt neue Daten auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) bekannt
Patienten mit blastischen plasmazytoiden dendritischen Zellneoplasien (BPDCN), die von Naveen Pemmaraju, MD, Professor, Abteilung für Leukämie, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, vorgestellt werden. Darüber hinaus wird Stemlines Partner, Karyopharm Therapeutics,
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:06 ET Menarini Group annonce de nouvelles données lors de la réunion annuelle 2026 de l'American Society of Clinical Oncology (ASCO)
dendritiques plasmacytoïdes (BPDCN) ont également été acceptées. Elles seront présentées par Naveen Pemmaraju, MD, professeur, département de leucémie, division de médecine du cancer, Université du Texas MD Anderson Cancer Center. En outre, le partenaire de Stemline, Karyopharm Therapeutics, présentera un exposé
More news about: Menarini Industrie Farmaceutiche Riunite
May 25, 2026, 08:03 ET Menarini Group Anuncia Novos Dados na Reunião Anual da American Society of Clinical Oncology (ASCO) 2026
de células dendríticas plasmocitoides blásticas (BPDCN), que serão apresentados por Naveen Pemmaraju, MD, Professor, Departamento de Leucemia, Divisão de Medicina do Câncer, The University of Texas MD Anderson Cancer Center. Além disso, o parceiro da Stemline, a Karyopharm Therapeutics, apresentará uma
More news about: Menarini Industrie Farmaceutiche Riunite